Firmonertinib in the Treatment of EGFR(+) NSCLC Patients With Central Nervous System Metastasis

NCT07239102 · clinicaltrials.gov ↗

COMPLETED

Status

300

Enrollment

OTHER

Sponsor class

Conditions

EGFR Positive Non-small Cell Lung Cancer
Central Nervous System Metastasis
Leptomeningeal Metastasis

Interventions

DRUG: Firmonertinib

Sponsor

Beijing Tiantan Hospital